MedTrace Logo

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

NCT00398320 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-03-01

Study results available
· View outcomes & findings →

Summary

Given the lack of other viable treatment options for metastatic neuroendocrine tumors, contrasted with our positive anecdotal experience, and the relative tolerability of the treatment regimen for colorectal cancer patients, we propose a single-institution phase II trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.

Conditions

Interventions

DRUG

Capecitabine

850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle

DRUG

Oxaliplatin

130 mg/m2 intravenously on day 1 of a 21 day cycle

DRUG

Bevacizumab

7.5mg/kg Intravenous on day 1 of a 21 day cycle

Sponsors & Collaborators

  • Pamela L. Kunz

    lead OTHER

Principal Investigators

  • Pamela L Kunz, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00398320 on ClinicalTrials.gov